NEW YORK (Reuters) – The Pfizer/BioNTech COVID-19 vaccine showed 90.7% efficacy against the coronavirus in a clinical trial of five to 11 year olds, the U.S. drugmaker said on Friday.
Sixteen children in the trial who had received a placebo got COVID-19, compared with 3 who were vaccinated, Pfizer said in briefing documents submitted to the U.S. Food and Drug Administration.
Because more than twice as many children in the 2,268-participant trial were given the vaccine than placebo, that equates to better than 90% efficacy.
Outside advisors to the FDA are scheduled to meet on Tuesday to vote on whether to recommend that the agency approve the vaccine for that age group.
(Reporting by Michael Erman; editing by John Stonestreet)
